美罗华联合CHOP方案治疗非霍奇金淋巴瘤的效果研究

Clinical effects of rituximab combined with CHOP regimen on patients with B cell non-Hodgkin's lymphoma

目的探讨美罗华联合CHOP方案(环磷酰胺+吡柔比星+长春新碱+泼尼松)治疗B细胞非霍奇金淋巴瘤(NHL)患者的临床效果。方法回顾性分析2011年1月至2015年12月60例NHL患者的临床资料,根据患者入院时间将其分为两组,分别给予单纯CHOP方案治疗(对照组30例)以及美罗华联合CHOP方案治疗(观察组30例),比较两组患者治疗效果差异。结果观察组缓解率(73.3%)高于对照组(53.3%),差异有统计学意义(P<0.05)。观察组不良反应发生率(26.7%)与对照组(63.3%)比较,差异有统计学意义(P<0.05)。观察组随访期间生存率(83.3%)高于对照组(66.7%)患者,差异有统计学意义(P<0.05)。结论美罗华联合CHOP方案治疗B细胞非霍奇金淋巴瘤患者效果显著,患者生存率、安全性均明显提高,值得临床推广。

Objective To investigate the effects of rituximab combined with CHOP regimen（ cyclophosphamide pirarubicin vincristine prednisone） on patients with B cell non-Hodgkin＇s lymphoma（ B cell NHL）. Methods The clinical data of 60 patients with B cell NHL from January 2011 to December 2015 were retrospectively analyzed. They were randomly divided into two groups,and with 30 cases in each group. The patients in the control group were treated with simple CHOP regimen,while the patients in the observation group were treated with rituximab combined with CHOP regimen. The therapeutic effects were compared between the two groups. Results After treatment,the remission rate of the observation group（ 73. 3%） was higher than that of the control group（ 53. 3%）,and the difference was significant（ P〈0. 05）. The incidence of adverse reactions in the observation group（ 26. 7%） was lower than that in the control group（ 63. 3%）,and the difference was significant（ P〈0. 05）. The survival rate of the observation group during follow-up period（ 83. 3%） was higher than that of the control group（ 66. 7%）,and the difference was significant（ P〈0. 05）. Conclusions In the treatment of patients with B cell non-Hodgkin lymphoma,the efficacy of rituximab combined with CHOP regimen is significant,the survival rate and safety can significantly improve,which is worthy of clinical promotion.